# IN THIS ISSUE



### nature publishing group

## nature REVIEWS



► COVER: 'Relative drug efficacy' by Susanne Harris, inspired by the Perspective on p277.





PETER KIRKPATRICK





CHARLOTTE HARRISON



**EDITORIAL OFFICES** 

The Macmillan Building,

Tel: +44 (0)20 7843 3620;

Fax: +44 (0)20 7843 3629

CHIEF EDITOR: Peter Kirkpatrick

SENIOR EDITORS: Alexandra Flemming,

SENIOR NEWS EDITOR: Bethan Hughes

SENIOR COPY EDITOR: Man Tsuey Tse

SENIOR ART EDITORS: Vicky Summersby,

ART CONTROLLER: Susanne Harris

MANAGING PRODUCTION EDITOR:

SENIOR PRODUCTION EDITOR:

PRODUCTION CONTROLLER:

ASSOCIATE EDITORS: Monica Hoyos Flight

Charlotte Harrison, Sarah Crunkhorn

4 Crinan Street.

Patrick Morgan

**Judith Shadwell** 

Simon Fenwick

Natalie Smith

London N1 9XW, UK

LONDON NatureReviews@nature.com

MONICA HOYOS FLIGHT

aining market access for new drugs is becoming increasingly challenging. Now, in addition to satisfying regulatory requirements for quality, safety and efficacy, a positive reimbursement decision by payers — typically based on the health benefits of the new drug relative to existing treatments, termed relative efficacy (RE) — is often needed. In their Perspective, Eichler and colleagues discuss the background to the RE debate, the methods and challenges of assessing RE, and the implications of RE for future drug development. Meanwhile, our reviews this month cover a variety of topics. Monoclonal antibodies (mAbs) are well established as a successful therapeutic modality, but carry a risk of inducing serious immune reactions as well as target-related adverse events. The safety of current mAbs and the future measures that could be taken to minimize the risk of side effects are reviewed by Hansel and colleagues. The potential of therapeutically targeting Toll-like receptors (TLRs) — using mAbs, small molecules or modified oligonucleotides — is currently receiving significant attention. O'Neill and colleagues summarize the roles of TLRs in mediating inflammation and disease, and review TLR isoform-specific agents under investigation for treating inflammatory and autoimmune diseases, viral and bacterial infections, as well as cancers. Another approach to treating various infections and cancers involves harnessing knowledge of cell-surface carbohydrate structures to develop novel vaccines. Astronomo and Burton describe specific pathogen- and tumour-associated carbohydrate targets, and discuss recent advances in addressing challenges associated with carbohydrate-based vaccine design and development. Finally, in his Perspective, Schneider considers the various issues that may be limiting the potential of virtual screening technologies to aid drug discovery

programmes, and proposes possible strategies to advance the field.

EDITORIAL ASSISTANTS: Jacques Smit, Laura Coms WEB PRODUCTION MANAGER: Deborah Anthony MARKETING MANAGERS: Tim Redding, Samantha Savalio

### **MANAGEMENT OFFICES**

LONDON nature@nature.com The Macmillan Building, 4 Crinan Street, London N1 9XW, UK Tel: +44 (0)20 7833 4000; Fax: +44 (0)20 7833 4596/7 OFFICE MANAGER: Laura Firman PUBLISHING DIRECTOR: Peter Collins MANAGING DIRECTOR: Steven Inchcoombe EDITOR-IN-CHIEF, NATURE PUBLICATIONS: Philip Campbell ASSOCIATE DIRECTORS: Jenny Henderson, Tony Rudland EDITORIAL PRODUCTION DIRECTOR: James McOuat PRODUCTION DIRECTOR: Yvonne Strong DIRECTOR, WEB PUBLISHING: Dan Pollock HEAD OF WEB PRODUCTION: Alexander Thurrell

NEW YORK nature@natureny.com Nature Publishing Group, 75 Varick Street, 9th floor, New York, NY 10013-1917, USA Tel: +1 212 726 9200 Fax: +1 212 696 9006 PUBLISHER (BIOPHARMA): Melanie Brazil CHIEF TECHNOLOGY OFFICER: Howard Ratner HEAD OF INTERNAL SYSTEMS DEVELOPMENT: Anthony Barrer HEAD OF SOFTWARE SERVICES: Luigi Squillante GLOBAL HEAD OF ADVERTISING AND SPONSORSHIP: Dean Sandersor HEAD OF NATURE RESEARCH & REVIEWS MARKETING: Sara Girard

#### TOKYO nature@natureasia.com Chiyoda Building 5F, 2-37-1 Ichigayatamachi, Shinjkuk-ku, Tokyo 162-0843, Japan Tel: +81 3 3267 8751; Fax: +81 3 3267 8746 ASIA-PACIFIC PUBLISHER: Antoine E Bocquet MANAGER: Koichi Nakamura ASIA-PACIFIC SALES DIRECTOR: Kate Yoneyama SENIOR MARKETING MANAGER: Peter Yoshihara MARKETING/PRODUCTION MANAGER: Takesh Murakami

INDIA 5A/12 Ansari Road, Daryganj, New Delhi 110 002, India Tel/Fax: +91 11 2324 4186 SALES AND MARKETING MANAGER, INDIA: Harpal Singh Gill Copyright © 2010 Nature Publishing Group

Copyright © 2010 Nature Publishing Group Research Highlight images courtesy of Getty Images unless otherwise credited. Printed in Wales by Cambrian Printers on acid-free paper